menu
    • menu
    [{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Denatonium Acetate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Denatonium Acetate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Pill","sponsorNew":"Aardvark Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"Denatonium Acetate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Denatonium Acetate","moa":"TAS2R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Aardvark Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Aardvark Therapeutics \/ Morgan Stanley"}]

    Find Clinical Drug Pipeline Developments & Deals for Denatonium Acetate

    Menu

    Denatonium Acetate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aardvark Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Aardvark Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $94.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aardvark Therapeutics Announces Pricing of Initial Public Offering

                            Details : The proceeds from the offering will be used to advance company's lead candidate molecule, ARD-101, as well as its secondary molecule ARD-201, both of which treat hyperphagia.

                            Product Name : ARD-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $94.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aardvark Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Aardvark Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $85.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing

                            Details : Aardvark intends to use proceeds for trials of ARD-101, a TAS2R pan-agonist for treating hyperphagia in patients with Prader-Willi Syndrome, required for regulatory approval of its lead asset.

                            Product Name : ARD-101

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 09, 2024

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $85.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aardvark Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Aardvark Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aardvark Therapeutics Announces Receipt of FDA Rare Pediatric Disease Designation for Prader-Willi Syndrome an...

                            Details : ARD-101, is a first-in-class oral composition that has shown promising activity in reducing hunger cravings in clinical studies and promoting weight loss in pre-clinical studies and which is investigated for the treatment of prader-willi yndrome.

                            Product Name : ARD-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2023

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aardvark Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Aardvark Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : University of California

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aardvark Therapeutics Reports Positive Phase II Clinical Data for ARD-101

                            Details : ARD-101 (denatonium acetate) is a first-in-class oral substantially gut-restricted with minimal systemic exposure yet conveys systemic effects via activation of GLP-1, GLP-2, and which show positive impact on hunger scores in general obesity and Prader-W...

                            Product Name : ARD-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : University of California

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth